NCT06980103Recruiting
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 408 (estimated)
- First submitted
- 8 Apr 2025
- Start date
- 6 Aug 2025
- Primary completion date
- 28 Feb 2029
- Lead sponsor
- Georgetown University
- Diseases
- Thyroid cancer
- NCT number
- NCT06980103
What you commit to
- Study type: Interventional
- Planned participants: 408
- From 6 Aug 2025 to the primary completion date, 28 Feb 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of RAI
Other
- Diagnosis of low risk or high risk DTC
- Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)
Who the study is looking for
- Patients aged 18 and older
- Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment
- Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate.
- Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Inova Health System Coordinator of this site? Confirm its status | Falls Church | United States | Recruiting |
| Lombardi Comprehensive Cancer Center Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
| MedStar Washington Hospital Center Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.